BRAF wild-type

The exploratory analysis of FIRE-3 suggests that the efficacy of cetuximab combined with FOLFIRI in RAS wild-type mCRC is related to sex and primary tumor sidedness. The results support the inclusion of patient sex into the design of future trials.

Pyrotinib plus trastuzumab demonstrates clinically meaningful efficacy and a manageable safety profile in heavily pretreated HER2-positive metastatic colorectal cancer. These findings support advancing this regimen as a potential alternative in refractory HER2-positive mCRC, particularly in the RAS/BRAF wild-type subgroup.

BRAF V600E is associated with inferior prognoses compared to BRAF WT in early-stage CC. This finding will help optimize trial design for this population.

Most cases lack germline MMR mutations in normal tissues but harbor somatic MMR mutations in tumor tissues. Germline or somatic mutations in other genes related to MMR function may be observed in some cases.

Our study provides a comprehensive genetic and molecular profile that closely recapitulates human diabetes. This system offers a valuable avenue for advancing basic research in the field of inflammation and regeneration within a diabetic context and promotes translational research for diabetes therapy.

The results showed that FOLFOXIRI combined with bevacizumab and atezolizumab significantly improved PFS and OS, with HRs for PFS and OS of (HR:0.19, 95% CI: 0.11-0.33), (HR:0.48, 95% CI: 0.30-0.78), respectively...These findings underscore the importance of integrating targeted drugs and immunotherapy in first-line mCRC treatments, highlighting significant differences in efficacy and safety profiles that can guide therapeutic decisions. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024604107, identifier CRD42024604107.

P1, N=2, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Dec 2025 --> Jul 2025

This atlas provides the most comprehensive transcriptional profiling of the developing inner ear, identifying new molecular leads to understand ear morphogenesis. Single-cell transcriptomic analysis of developing wild-type and lmx1bb mutant zebrafish reveals cell-states and effectors that distinguish the inner ear's sensory patches, semicircular canals, endolymphatic duct and sac, and periotic mesenchyme.

CMS4 might be an additional biomarker of anti-EGFR treatment efficacy in RAS (and BRAF) WT mCRC.

Our data suggest that MSI/dMMR CRCs harboring RASmut are less immunogenic and TiME contains a lower inflammatory profile than wild-type or BRAFV600E tumors. Further analysis and validation are required to confirm these findings.

We report the case of a 32-year-old man who presented with a pituitary stalk mass and ventricular dissemination, ultimately diagnosed with BRAF wild-type ECD harboring a CSF1R mutation, which has recently been implicated as a potential driver within the MAPK pathway. A deeper understanding of the molecular pathogenesis of ECD may not only aid in accurate diagnosis but also contribute to improved clinical outcomes.

Selecting patients with left-sided RAS/BRAF wt mCRC resulted in a 92% clinical benefit rate from anti-EGFR mAb monotherapy. Early [ 18F]FDG PET/CT identified non-responders with 100% accuracy, offering promising clinical utility when tumor mutational status is unavailable.